Nature Communications (Aug 2018)
Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
- William T. Ralvenius,
- Elena Neumann,
- Martina Pagani,
- Mario A. Acuña,
- Hendrik Wildner,
- Dietmar Benke,
- Nina Fischer,
- Ana Rostaher,
- Simon Schwager,
- Michael Detmar,
- Katrin Frauenknecht,
- Adriano Aguzzi,
- Jed Lee Hubbs,
- Uwe Rudolph,
- Claude Favrot,
- Hanns Ulrich Zeilhofer
Affiliations
- William T. Ralvenius
- Institute of Pharmacology and Toxicology, University of Zürich
- Elena Neumann
- Institute of Pharmacology and Toxicology, University of Zürich
- Martina Pagani
- Institute of Pharmacology and Toxicology, University of Zürich
- Mario A. Acuña
- Institute of Pharmacology and Toxicology, University of Zürich
- Hendrik Wildner
- Institute of Pharmacology and Toxicology, University of Zürich
- Dietmar Benke
- Institute of Pharmacology and Toxicology, University of Zürich
- Nina Fischer
- Dermatology Department, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty
- Ana Rostaher
- Dermatology Department, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty
- Simon Schwager
- Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich
- Michael Detmar
- Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich
- Katrin Frauenknecht
- Institute of Neuropathology, University of Zürich and University Hospital Zürich
- Adriano Aguzzi
- Institute of Neuropathology, University of Zürich and University Hospital Zürich
- Jed Lee Hubbs
- Laboratory of Organic Chemistry, Swiss Federal Institute of Technology (ETH) Zürich
- Uwe Rudolph
- Laboratory of Genetic Neuropharmacology, McLean Hospital
- Claude Favrot
- Dermatology Department, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty
- Hanns Ulrich Zeilhofer
- Institute of Pharmacology and Toxicology, University of Zürich
- DOI
- https://doi.org/10.1038/s41467-018-05709-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Chronic itch affects about 10% of the general population, however current treatments are largely ineffective. Here, the authors show that targeting of inhibitory α2 and α3GABAA receptors reduces itch in mice and in a canine model, suggesting this a potentially useful therapeutic approach.
